Production (Stage)
Pelthos Therapeutics Inc.
PTHS
$20.30
-$1.83-8.27%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -272.30K | 0.00 | 609.00K | 243.50K | 280.50K |
| Gross Profit | 272.30K | 0.00 | -609.00K | -243.50K | -280.50K |
| SG&A Expenses | 6.56M | 6.39M | 6.44M | 6.05M | 5.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.47M | 7.57M | 9.63M | 8.87M | 7.88M |
| Operating Income | -7.47M | -7.57M | -9.63M | -8.87M | -7.88M |
| Income Before Tax | -7.36M | -7.96M | -10.07M | -9.79M | -8.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.36 | -7.96 | -10.07 | -9.79 | -8.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.36M | -7.96M | -10.07M | -9.79M | -8.98M |
| EBIT | -7.47M | -7.57M | -9.63M | -8.87M | -7.88M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -12.40 | -14.65 | -31.56 | -43.08 | -49.51 |
| Normalized Basic EPS | -8.14 | -9.55 | -20.12 | -26.92 | -30.95 |
| EPS Diluted | -12.40 | -14.65 | -31.56 | -43.08 | -49.51 |
| Normalized Diluted EPS | -8.14 | -9.55 | -20.12 | -26.92 | -30.95 |
| Average Basic Shares Outstanding | 2.37M | 2.23M | 1.83M | 1.35M | 868.80K |
| Average Diluted Shares Outstanding | 2.37M | 2.23M | 1.83M | 1.35M | 868.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |